Page 3 - Juergen Eckhardt News Today

LONDON and NEW YORK  , May 12, 2021 /PRNewswire/ -- Huma Therapeutics Limited today announces the completion of its latest funding round with financing of approximately $130 million. The investment will scale Humas modular platform which can power digital hospitals at home nationally, and support the pharmaceutical and research industries to run the largest ever decentralized clinical trials. Humas platform combines predictive algorithms, digital biomarkers and real-world data to advan...

Huma, which uses AI and biomarkers to monitor patients and for medical research, raises $130M While much of the world eagerly watches to see if the vaccination rollout helps curb and eventually stamp out Covid-19, one of the companies that has been helping to manage the spread of the virus is announcing a big round of funding on the heels for strong demand for its technology. Huma, which combines data from biomarkers with predictive algorithms both to help monitor patients, and uses the same te...

The funds will be used to scale its remote monitoring platform.

Edifice, a Healthcare Disruptor spun out of Stanford, Raises $12 Million to Reinvent Immune Health, Improve Healthspan, and Change Course of Aging News provided by Share this article Share this article SAN MATEO, Calif., April 22, 2021 /PRNewswire/ -- Edifice Health, a Silicon Valley emerging company in immunological health and personalized nutrition, today announced a $12 Million investment, led by Leaps by Bayer. Through its highly-differentiated approach, Edifice aims to harness previously...

Ukko Secures $40 Million in Series B Funding Led by Leaps by Bayer to Overcome Food Allergies and Sensitivities Top industry leaders and venture firms unite behind Ukkos efforts to eliminate the worlds most prevalent food allergies and sensitivities, including peanuts and gluten News provided by Share this article Share this article PALO ALTO, Calif., TEL AVIV, Israel and LEVERKUSEN, Germany, Jan. 27, 2021 /PRNewswire/ -- Ukko, a biotech company with the mission to eliminate food allergies and ...

Bayer leads $40m investment in Israeli biotech co Ukko The funding will allow Ukko to begin clinical trials on its peanut allergy therapy and develop is celiac and gluten sensitivity treatment. Israeli biotech company Ukko, which is working to eliminate food allergies and sensitivities, today announced the completion of a $40 million Series B financing round. The round was led by Bayers impact investment arm Leaps, with the participation of Continental Grain Company, PeakBridge Ventures, Skyvie...

Bayer plans 3 new drugs, banks on gene and cell therapy allogeneic cancer medicines PUBLISHED BY Bayer has plans to introduce three news drugs with annual sales potential of $1.22 billion (€1 billion) but these will not offset the fall in revenue the company anticipates from the loss of patents over its two best-sellers. Stefan Oelrich, the company head, who joined in 2018 from rival Sanofi, acknowledged that the new drugs would not compensate for the effects of the forthcoming patent expi...

(2) Senti Bios gene circuit technology platform has the potential to optimize cell and gene therapies across delivery modalities and therapeutic areas Proceeds to support platform expansion and advance multiple allogeneic CAR-NK cell therapy pipeline candidates for difficult-to-treat cancers, including acute myeloid leukemia and hepatocellular carcinoma Leaps by Bayer and Senti Biosciences, Inc., a leading gene circuit company, today announced a USD 105 million Series B financing round. The fin...

Dive Brief: Bayers venture investment arm is leading a $105 million funding round in closely held Senti Biosciences, a California-based company using synthetic biology to develop off-the-shelf cell therapies for cancer. It is at least the third cell therapy company to receive investment from Bayer, which has since acquired one of those companies. Senti is advancing two experimental treatments using "natural killer" immune cells to attack tumors in leukemia and liver cancer. The company believes...

Press release content from Business Wire. The AP news staff was not involved in its creation. Atomwise and FutuRx Launch A2i Therapeutics - A New Immuno-Oncology Company Funded By Leading Biopharma VCs and the Israeli Innovation Authority December 18, 2020 GMT SAN FRANCISCO & NESS ZIONA, Israel--(BUSINESS WIRE)--Dec 18, 2020-- Atomwise, the leader in using artificial intelligence (AI) for small-molecule drug discovery, announced today a partnership with FutuRx, a recognized Israeli-based biotec...